• Skip to main content
  • Skip to footer

Accuronix

Developing novel cancer therapies

  • Home
  • Founders
  • Approach
  • Contact

Founders

William HawkinsWilliam Hawkins, MD

  • Neidorff­ Family and Robert C. Packman Professor of Surgery
  • Chief, Section of Hepatobiliary, Pancreatic, & Gastrointestinal Surgery
  • Washington University School of Medicine


Robert MachRobert Mach, PhD

  • Britton Chance Professor of Radiology
  • University of Pennsylvania

Dr. Mach and Dr. Hawkins have collaborated for more than 10 years to extend Dr. Mach’s discoveries about the σ-2 receptor in cancer cells into the development of novel therapeutic modalities for pancreatic adenocarcinoma and a wide range of other tumor types.

Footer

About Us

We are applying a novel drug-targeting technology to some of the most difficult problems in cancer therapy.

News & Publications
Financial Conflicts of Interest (FCOI)

Mission

With an initial focus in pancreatic cancer, the Company’s mission is to develop novel oncology therapies based on technology that selectively targets σ-2 receptors overexpressed on cancer cells

Partners

Washington University | University of Pennsylvania | BioGenerator

Contact Us

Accuronix Therapeutics
4340 Duncan Ave.
Suite 210
St. Louis, MO 63110

Contact
Bradley T. Keller, Ph.D.
President and CEO
[email protected]

Copyright © 2023 Accuronix.com · Powered by NeuConcept